NO975887L - Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem - Google Patents

Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem

Info

Publication number
NO975887L
NO975887L NO975887A NO975887A NO975887L NO 975887 L NO975887 L NO 975887L NO 975887 A NO975887 A NO 975887A NO 975887 A NO975887 A NO 975887A NO 975887 L NO975887 L NO 975887L
Authority
NO
Norway
Prior art keywords
processes
preparation
stands
carbon atoms
sulfonamide
Prior art date
Application number
NO975887A
Other languages
English (en)
Other versions
NO975887D0 (no
Inventor
Joachim Brendel
Hans Jochen Lang
Uwe Gerlach
Klaus Weidmann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996152213 external-priority patent/DE19652213A1/de
Priority claimed from DE1997130326 external-priority patent/DE19730326A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO975887D0 publication Critical patent/NO975887D0/no
Publication of NO975887L publication Critical patent/NO975887L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/161,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Forbindelser med formel I (I) hvor X står for -O-, -S-, -SO-, -S02-, -NR(7)-, -CR(8a)R(8b)- eller -CO-; Y står for N eller CR(11); R(l) og R(2) står uavhengig av hverandre for CF3, C2F5, C3F7, F, Cl, metoksy, alkyl med l til 6 karbonatomer eller fenyl, som eventuelt er substituert; eller R(l) og R(2) står sammen for en alkylenkjede med 2 til 10 karbonatomer; R(3) står for R(12)- Cn-H2n-NR(13) eller R(12)-CnH2n-, eller R(3) og R(4) er sammen en alkylenkjede med 3 til 8 karbonatomer, hvor en CH2-gruppe eventuelt kan være byttet ut; R(4) er R(14)- CrHj,. og R(59 og R(6) er sammen en gruppe -CR(15)=CR816)-CR(17)=CR(18)-, -CR(15)=CR( 16)-CR(17)=N-, -CR(15)=CR(16)-N=CR(18)-, -CR(15)=N-CR(17)=N-, -CR(15)=N-N=CR(18)-, -N=CR(16)-CR(17)=N- eller-S-CR(15)=CR(16)-; samt deres farmasøytisk akseptable salter, er utmerkede aktive stoffer for fremstilling av medika- menter for profylakse og terapi av kardiovaskulære forstyrrelser, spesielt arrytmier, for behandling av sår i den gastrointestinale trakt eller for behandling av diarésykdommer. Det blir dessuten beskrevet fremgangsmåter for fremstilling av disse forbindelsene.
NO975887A 1996-12-16 1997-12-15 Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem NO975887L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996152213 DE19652213A1 (de) 1996-12-16 1996-12-16 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE1997130326 DE19730326A1 (de) 1997-07-15 1997-07-15 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Publications (2)

Publication Number Publication Date
NO975887D0 NO975887D0 (no) 1997-12-15
NO975887L true NO975887L (no) 1998-06-17

Family

ID=26032247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975887A NO975887L (no) 1996-12-16 1997-12-15 Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem

Country Status (24)

Country Link
US (1) US5856338A (no)
EP (1) EP0847996B1 (no)
JP (1) JP4317601B2 (no)
KR (1) KR19980064151A (no)
CN (1) CN1185435A (no)
AT (1) ATE234821T1 (no)
AU (1) AU725699B2 (no)
BR (1) BR9706142A (no)
CA (1) CA2224885A1 (no)
CZ (1) CZ403997A3 (no)
DE (1) DE59709560D1 (no)
DK (1) DK0847996T3 (no)
ES (1) ES2195071T3 (no)
HR (1) HRP970684A2 (no)
HU (1) HUP9702475A3 (no)
ID (1) ID19152A (no)
IL (1) IL122576A0 (no)
NO (1) NO975887L (no)
NZ (1) NZ329200A (no)
PL (1) PL323809A1 (no)
PT (1) PT847996E (no)
SI (1) SI0847996T1 (no)
SK (1) SK171797A3 (no)
TR (1) TR199701605A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
AU5542101A (en) 2000-04-14 2001-10-30 Univ Vanderbilt Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CN113402476B (zh) * 2021-06-21 2022-04-19 广东湛江海洋医药研究院 一种亚胺噁嗪衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737195A1 (de) * 1987-11-03 1989-05-18 Bayer Ag Chromanderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB8808069D0 (en) * 1988-04-07 1988-05-11 Fujisawa Pharmaceutical Co Benzopyran derivatives & processes for preparation thereof
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
ES2145129T3 (es) * 1992-08-17 2000-07-01 Chugai Pharmaceutical Co Ltd Derivados de benzopirano y benzoxazina.
PT807629E (pt) * 1996-05-15 2004-07-30 Aventis Pharma Gmbh Cromanos substituidos por sulfonamidas processo para a sua preparacao a sua utilizacao como medicamentos ou agentes de diagnostico bem como medicamentos que os contem

Also Published As

Publication number Publication date
MX9710126A (es) 1998-07-31
HRP970684A2 (en) 1998-10-31
AU725699B2 (en) 2000-10-19
SI0847996T1 (en) 2003-08-31
CA2224885A1 (en) 1998-06-16
SK171797A3 (en) 1998-07-08
DK0847996T3 (da) 2003-06-30
HUP9702475A2 (hu) 1999-06-28
HUP9702475A3 (en) 2000-01-28
EP0847996B1 (de) 2003-03-19
ID19152A (id) 1998-06-18
NO975887D0 (no) 1997-12-15
IL122576A0 (en) 1998-06-15
ES2195071T3 (es) 2003-12-01
TR199701605A2 (xx) 1998-07-21
ATE234821T1 (de) 2003-04-15
BR9706142A (pt) 1999-05-18
PT847996E (pt) 2003-07-31
DE59709560D1 (de) 2003-04-24
PL323809A1 (en) 1998-06-22
US5856338A (en) 1999-01-05
CN1185435A (zh) 1998-06-24
CZ403997A3 (cs) 1998-07-15
JPH10182610A (ja) 1998-07-07
NZ329200A (en) 1999-05-28
AU4837397A (en) 1998-06-18
JP4317601B2 (ja) 2009-08-19
EP0847996A1 (de) 1998-06-17
HU9702475D0 (en) 1998-03-02
KR19980064151A (ko) 1998-10-07

Similar Documents

Publication Publication Date Title
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SE0104340D0 (sv) New compounds
BR0211228A (pt) Composto, composição farmacêutica e seus usos
CA2223403A1 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
IL154536A0 (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
JPH06500078A (ja) Tnf抑制剤
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
US20030050329A1 (en) Synergistic combination comprising roflumilast and a PDE-3 inhibitor
NO975887L (no) Sulfonamidsubstituerte forbindelser, fremgangsmÕte for deres fremstilling, deres anvendelse som et medikament eller diagnostikum, og farmas°ytiske sammensetninger inneholdende dem
WO1989005637A1 (en) Improving toxicity profiles in chemotherapy
SE9901572D0 (sv) New compounds
CA1327163C (en) Anxiolytically active piperazine derivatives
SE0201837D0 (sv) Chemical compounds
EP0664127B1 (en) Pharmaceutical compositions containing isoquinoline derivatives
Spina et al. The role of platelet activating factor in allergic inflammation
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
RU95102147A (ru) Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав
ES2134441T3 (es) Benzonitrilos terapeuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application